Influence of blood-brain barrier permeability on O-(2-18F-fluoroethyl)-L-tyrosine uptake in rat gliomas
Purpose O-(2- 18 F-fluoroethyl)-L-tyrosine ( 18 F-FET) is an established tracer for the diagnosis of brain tumors with PET. This study investigates the influence of blood-brain barrier (BBB) permeability on 18 F-FET uptake in two rat glioma models and one human xenograft model. Methods F98 glioma, 9...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2017-03, Vol.44 (3), p.408-416 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 416 |
|---|---|
| container_issue | 3 |
| container_start_page | 408 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 44 |
| creator | Stegmayr, Carina Bandelow, Ulrike Oliveira, Dennis Lohmann, Philipp Willuweit, Antje Filss, Christian Galldiks, Norbert Lübke, Joachim H. R. Shah, N. Jon Ermert, Johannes Langen, Karl-Josef |
| description | Purpose
O-(2-
18
F-fluoroethyl)-L-tyrosine (
18
F-FET) is an established tracer for the diagnosis of brain tumors with PET. This study investigates the influence of blood-brain barrier (BBB) permeability on
18
F-FET uptake in two rat glioma models and one human xenograft model.
Methods
F98 glioma, 9L gliosarcoma or human U87 glioblastoma cells were implanted into the striatum of 56 Fischer or RNU rats. Thereafter, animals were divided into a control group and a group receiving injections of the glucocorticoid dexamethasone (Dex). After 12-13 days of tumor growth animals received injection of Evans blue dye (EBD) to visualize BBB disturbance and underwent
18
F-FET PET followed by autoradiography. Time activity curves, standardized uptake values (SUV) and Tumor-to-brain ratios (TBR) of
18
F-FET uptake [18-61 min post injection (p.i.)] were evaluated using a volume-of-Interest (VOI) analysis. BBB disturbance was quantitatively evaluated by EBD fluorescence. The membrane gaps of blood vessel endothelial tight junctions were measured using electron microscopy to visualize ultrastructural BBB alterations in one untreated and one Dex treated F98 glioma. Data were analyzed by two-way ANOVAs.
Results
In Dex treated animals EBD extravasation was significantly reduced in 9L (
P
|
| doi_str_mv | 10.1007/s00259-016-3508-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1859732303</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4312388061</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-5212751a170f8b5164628793a8fb905c96381c8b51177e357bef225c95182bd33</originalsourceid><addsrcrecordid>eNp1kU9P3DAQxS1UxJ8tH6CXylIvcDCdsXHsHCtUCtJKe4GzZWcnS2gSb-3ksN8er5aiqhInW57fezPjx9gXhGsEMN8zgNS1AKyE0mAFHLEzrLAWBmz96f1u4JSd5_wCgFba-oSdSlOh0jd4xjYPY9vPNDbEY8tDH-NahOS7kQefUkeJbykN5EPXd9OOx5GvxKUUaO9E0cUUaXre9VdiKaZdirkbic_byf8mXiySn_im7-Lg82d23Po-08XbuWBPdz8fb-_FcvXr4fbHUjTKyEloidJo9GigtUFjdVNJa2rlbRtq0E1dKYvNvoLGkNImUCtleddltbBWasEuD77bFP_MlCc3dLmhvvcjxTk7tLo2SirYo9_-Q1_inMYyXaEqLXWltC0UHqimrJcTtW6busGnnUNw-xTcIQVXUnD7FBwUzdc35zkMtH5X_P32AsgDkEtp3FD6p_WHrq-FRY95</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1865256358</pqid></control><display><type>article</type><title>Influence of blood-brain barrier permeability on O-(2-18F-fluoroethyl)-L-tyrosine uptake in rat gliomas</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Stegmayr, Carina ; Bandelow, Ulrike ; Oliveira, Dennis ; Lohmann, Philipp ; Willuweit, Antje ; Filss, Christian ; Galldiks, Norbert ; Lübke, Joachim H. R. ; Shah, N. Jon ; Ermert, Johannes ; Langen, Karl-Josef</creator><creatorcontrib>Stegmayr, Carina ; Bandelow, Ulrike ; Oliveira, Dennis ; Lohmann, Philipp ; Willuweit, Antje ; Filss, Christian ; Galldiks, Norbert ; Lübke, Joachim H. R. ; Shah, N. Jon ; Ermert, Johannes ; Langen, Karl-Josef</creatorcontrib><description>Purpose
O-(2-
18
F-fluoroethyl)-L-tyrosine (
18
F-FET) is an established tracer for the diagnosis of brain tumors with PET. This study investigates the influence of blood-brain barrier (BBB) permeability on
18
F-FET uptake in two rat glioma models and one human xenograft model.
Methods
F98 glioma, 9L gliosarcoma or human U87 glioblastoma cells were implanted into the striatum of 56 Fischer or RNU rats. Thereafter, animals were divided into a control group and a group receiving injections of the glucocorticoid dexamethasone (Dex). After 12-13 days of tumor growth animals received injection of Evans blue dye (EBD) to visualize BBB disturbance and underwent
18
F-FET PET followed by autoradiography. Time activity curves, standardized uptake values (SUV) and Tumor-to-brain ratios (TBR) of
18
F-FET uptake [18-61 min post injection (p.i.)] were evaluated using a volume-of-Interest (VOI) analysis. BBB disturbance was quantitatively evaluated by EBD fluorescence. The membrane gaps of blood vessel endothelial tight junctions were measured using electron microscopy to visualize ultrastructural BBB alterations in one untreated and one Dex treated F98 glioma. Data were analyzed by two-way ANOVAs.
Results
In Dex treated animals EBD extravasation was significantly reduced in 9L (
P
< 0.001) and U87 (
P
= 0.008) models and showed a trend in F98 models (
P
= 0.053). In contrast, no significant differences of
18
F-FET uptake were observed between Dex treated animals and control group except a decrease of the TBR in the 9L tumor model in PET (
P
< 0.01). Ultrastructural evaluation of tumor blood vessel endothelia revealed significant reduction of the cleft diameter between endothelial cells after Dex treatment in F98 model (
P
= 0.010).
Conclusion
Despite a considerable reduction of BBB permeability in rat gliomas after Dex treatment, no relevant changes of
18
F-FET uptake were noted in this experimental study. Thus,
18
F-FET uptake in gliomas appears to be widely independent of the permeability of the BBB.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-016-3508-0</identifier><identifier>PMID: 27613541</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Animals ; Antineoplastic Agents, Hormonal - adverse effects ; Blood-brain barrier ; Blood-Brain Barrier - diagnostic imaging ; Blood-Brain Barrier - drug effects ; Blood-Brain Barrier - metabolism ; Brain cancer ; Capillary Permeability ; Cardiology ; Cell Line, Tumor ; Dexamethasone - adverse effects ; Glioma - diagnostic imaging ; Humans ; Imaging ; Male ; Medicine ; Medicine & Public Health ; Nuclear Medicine ; Oncology ; Original Article ; Orthopedics ; Radiology ; Radiopharmaceuticals - pharmacokinetics ; Rats ; Rodents ; Tight Junctions - metabolism ; Tight Junctions - ultrastructure ; Tomography ; Tyrosine - analogs & derivatives ; Tyrosine - pharmacokinetics</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2017-03, Vol.44 (3), p.408-416</ispartof><rights>Springer-Verlag Berlin Heidelberg 2016</rights><rights>European Journal of Nuclear Medicine and Molecular Imaging is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-5212751a170f8b5164628793a8fb905c96381c8b51177e357bef225c95182bd33</citedby><cites>FETCH-LOGICAL-c372t-5212751a170f8b5164628793a8fb905c96381c8b51177e357bef225c95182bd33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-016-3508-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-016-3508-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27928,27929,41492,42561,51323</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27613541$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stegmayr, Carina</creatorcontrib><creatorcontrib>Bandelow, Ulrike</creatorcontrib><creatorcontrib>Oliveira, Dennis</creatorcontrib><creatorcontrib>Lohmann, Philipp</creatorcontrib><creatorcontrib>Willuweit, Antje</creatorcontrib><creatorcontrib>Filss, Christian</creatorcontrib><creatorcontrib>Galldiks, Norbert</creatorcontrib><creatorcontrib>Lübke, Joachim H. R.</creatorcontrib><creatorcontrib>Shah, N. Jon</creatorcontrib><creatorcontrib>Ermert, Johannes</creatorcontrib><creatorcontrib>Langen, Karl-Josef</creatorcontrib><title>Influence of blood-brain barrier permeability on O-(2-18F-fluoroethyl)-L-tyrosine uptake in rat gliomas</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose
O-(2-
18
F-fluoroethyl)-L-tyrosine (
18
F-FET) is an established tracer for the diagnosis of brain tumors with PET. This study investigates the influence of blood-brain barrier (BBB) permeability on
18
F-FET uptake in two rat glioma models and one human xenograft model.
Methods
F98 glioma, 9L gliosarcoma or human U87 glioblastoma cells were implanted into the striatum of 56 Fischer or RNU rats. Thereafter, animals were divided into a control group and a group receiving injections of the glucocorticoid dexamethasone (Dex). After 12-13 days of tumor growth animals received injection of Evans blue dye (EBD) to visualize BBB disturbance and underwent
18
F-FET PET followed by autoradiography. Time activity curves, standardized uptake values (SUV) and Tumor-to-brain ratios (TBR) of
18
F-FET uptake [18-61 min post injection (p.i.)] were evaluated using a volume-of-Interest (VOI) analysis. BBB disturbance was quantitatively evaluated by EBD fluorescence. The membrane gaps of blood vessel endothelial tight junctions were measured using electron microscopy to visualize ultrastructural BBB alterations in one untreated and one Dex treated F98 glioma. Data were analyzed by two-way ANOVAs.
Results
In Dex treated animals EBD extravasation was significantly reduced in 9L (
P
< 0.001) and U87 (
P
= 0.008) models and showed a trend in F98 models (
P
= 0.053). In contrast, no significant differences of
18
F-FET uptake were observed between Dex treated animals and control group except a decrease of the TBR in the 9L tumor model in PET (
P
< 0.01). Ultrastructural evaluation of tumor blood vessel endothelia revealed significant reduction of the cleft diameter between endothelial cells after Dex treatment in F98 model (
P
= 0.010).
Conclusion
Despite a considerable reduction of BBB permeability in rat gliomas after Dex treatment, no relevant changes of
18
F-FET uptake were noted in this experimental study. Thus,
18
F-FET uptake in gliomas appears to be widely independent of the permeability of the BBB.</description><subject>Animals</subject><subject>Antineoplastic Agents, Hormonal - adverse effects</subject><subject>Blood-brain barrier</subject><subject>Blood-Brain Barrier - diagnostic imaging</subject><subject>Blood-Brain Barrier - drug effects</subject><subject>Blood-Brain Barrier - metabolism</subject><subject>Brain cancer</subject><subject>Capillary Permeability</subject><subject>Cardiology</subject><subject>Cell Line, Tumor</subject><subject>Dexamethasone - adverse effects</subject><subject>Glioma - diagnostic imaging</subject><subject>Humans</subject><subject>Imaging</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Radiology</subject><subject>Radiopharmaceuticals - pharmacokinetics</subject><subject>Rats</subject><subject>Rodents</subject><subject>Tight Junctions - metabolism</subject><subject>Tight Junctions - ultrastructure</subject><subject>Tomography</subject><subject>Tyrosine - analogs & derivatives</subject><subject>Tyrosine - pharmacokinetics</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kU9P3DAQxS1UxJ8tH6CXylIvcDCdsXHsHCtUCtJKe4GzZWcnS2gSb-3ksN8er5aiqhInW57fezPjx9gXhGsEMN8zgNS1AKyE0mAFHLEzrLAWBmz96f1u4JSd5_wCgFba-oSdSlOh0jd4xjYPY9vPNDbEY8tDH-NahOS7kQefUkeJbykN5EPXd9OOx5GvxKUUaO9E0cUUaXre9VdiKaZdirkbic_byf8mXiySn_im7-Lg82d23Po-08XbuWBPdz8fb-_FcvXr4fbHUjTKyEloidJo9GigtUFjdVNJa2rlbRtq0E1dKYvNvoLGkNImUCtleddltbBWasEuD77bFP_MlCc3dLmhvvcjxTk7tLo2SirYo9_-Q1_inMYyXaEqLXWltC0UHqimrJcTtW6busGnnUNw-xTcIQVXUnD7FBwUzdc35zkMtH5X_P32AsgDkEtp3FD6p_WHrq-FRY95</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Stegmayr, Carina</creator><creator>Bandelow, Ulrike</creator><creator>Oliveira, Dennis</creator><creator>Lohmann, Philipp</creator><creator>Willuweit, Antje</creator><creator>Filss, Christian</creator><creator>Galldiks, Norbert</creator><creator>Lübke, Joachim H. R.</creator><creator>Shah, N. Jon</creator><creator>Ermert, Johannes</creator><creator>Langen, Karl-Josef</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20170301</creationdate><title>Influence of blood-brain barrier permeability on O-(2-18F-fluoroethyl)-L-tyrosine uptake in rat gliomas</title><author>Stegmayr, Carina ; Bandelow, Ulrike ; Oliveira, Dennis ; Lohmann, Philipp ; Willuweit, Antje ; Filss, Christian ; Galldiks, Norbert ; Lübke, Joachim H. R. ; Shah, N. Jon ; Ermert, Johannes ; Langen, Karl-Josef</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-5212751a170f8b5164628793a8fb905c96381c8b51177e357bef225c95182bd33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Antineoplastic Agents, Hormonal - adverse effects</topic><topic>Blood-brain barrier</topic><topic>Blood-Brain Barrier - diagnostic imaging</topic><topic>Blood-Brain Barrier - drug effects</topic><topic>Blood-Brain Barrier - metabolism</topic><topic>Brain cancer</topic><topic>Capillary Permeability</topic><topic>Cardiology</topic><topic>Cell Line, Tumor</topic><topic>Dexamethasone - adverse effects</topic><topic>Glioma - diagnostic imaging</topic><topic>Humans</topic><topic>Imaging</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Radiology</topic><topic>Radiopharmaceuticals - pharmacokinetics</topic><topic>Rats</topic><topic>Rodents</topic><topic>Tight Junctions - metabolism</topic><topic>Tight Junctions - ultrastructure</topic><topic>Tomography</topic><topic>Tyrosine - analogs & derivatives</topic><topic>Tyrosine - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stegmayr, Carina</creatorcontrib><creatorcontrib>Bandelow, Ulrike</creatorcontrib><creatorcontrib>Oliveira, Dennis</creatorcontrib><creatorcontrib>Lohmann, Philipp</creatorcontrib><creatorcontrib>Willuweit, Antje</creatorcontrib><creatorcontrib>Filss, Christian</creatorcontrib><creatorcontrib>Galldiks, Norbert</creatorcontrib><creatorcontrib>Lübke, Joachim H. R.</creatorcontrib><creatorcontrib>Shah, N. Jon</creatorcontrib><creatorcontrib>Ermert, Johannes</creatorcontrib><creatorcontrib>Langen, Karl-Josef</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stegmayr, Carina</au><au>Bandelow, Ulrike</au><au>Oliveira, Dennis</au><au>Lohmann, Philipp</au><au>Willuweit, Antje</au><au>Filss, Christian</au><au>Galldiks, Norbert</au><au>Lübke, Joachim H. R.</au><au>Shah, N. Jon</au><au>Ermert, Johannes</au><au>Langen, Karl-Josef</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of blood-brain barrier permeability on O-(2-18F-fluoroethyl)-L-tyrosine uptake in rat gliomas</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2017-03-01</date><risdate>2017</risdate><volume>44</volume><issue>3</issue><spage>408</spage><epage>416</epage><pages>408-416</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose
O-(2-
18
F-fluoroethyl)-L-tyrosine (
18
F-FET) is an established tracer for the diagnosis of brain tumors with PET. This study investigates the influence of blood-brain barrier (BBB) permeability on
18
F-FET uptake in two rat glioma models and one human xenograft model.
Methods
F98 glioma, 9L gliosarcoma or human U87 glioblastoma cells were implanted into the striatum of 56 Fischer or RNU rats. Thereafter, animals were divided into a control group and a group receiving injections of the glucocorticoid dexamethasone (Dex). After 12-13 days of tumor growth animals received injection of Evans blue dye (EBD) to visualize BBB disturbance and underwent
18
F-FET PET followed by autoradiography. Time activity curves, standardized uptake values (SUV) and Tumor-to-brain ratios (TBR) of
18
F-FET uptake [18-61 min post injection (p.i.)] were evaluated using a volume-of-Interest (VOI) analysis. BBB disturbance was quantitatively evaluated by EBD fluorescence. The membrane gaps of blood vessel endothelial tight junctions were measured using electron microscopy to visualize ultrastructural BBB alterations in one untreated and one Dex treated F98 glioma. Data were analyzed by two-way ANOVAs.
Results
In Dex treated animals EBD extravasation was significantly reduced in 9L (
P
< 0.001) and U87 (
P
= 0.008) models and showed a trend in F98 models (
P
= 0.053). In contrast, no significant differences of
18
F-FET uptake were observed between Dex treated animals and control group except a decrease of the TBR in the 9L tumor model in PET (
P
< 0.01). Ultrastructural evaluation of tumor blood vessel endothelia revealed significant reduction of the cleft diameter between endothelial cells after Dex treatment in F98 model (
P
= 0.010).
Conclusion
Despite a considerable reduction of BBB permeability in rat gliomas after Dex treatment, no relevant changes of
18
F-FET uptake were noted in this experimental study. Thus,
18
F-FET uptake in gliomas appears to be widely independent of the permeability of the BBB.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>27613541</pmid><doi>10.1007/s00259-016-3508-0</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2017-03, Vol.44 (3), p.408-416 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1859732303 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Animals Antineoplastic Agents, Hormonal - adverse effects Blood-brain barrier Blood-Brain Barrier - diagnostic imaging Blood-Brain Barrier - drug effects Blood-Brain Barrier - metabolism Brain cancer Capillary Permeability Cardiology Cell Line, Tumor Dexamethasone - adverse effects Glioma - diagnostic imaging Humans Imaging Male Medicine Medicine & Public Health Nuclear Medicine Oncology Original Article Orthopedics Radiology Radiopharmaceuticals - pharmacokinetics Rats Rodents Tight Junctions - metabolism Tight Junctions - ultrastructure Tomography Tyrosine - analogs & derivatives Tyrosine - pharmacokinetics |
| title | Influence of blood-brain barrier permeability on O-(2-18F-fluoroethyl)-L-tyrosine uptake in rat gliomas |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T14%3A15%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20blood-brain%20barrier%20permeability%20on%20O-(2-18F-fluoroethyl)-L-tyrosine%20uptake%20in%20rat%20gliomas&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Stegmayr,%20Carina&rft.date=2017-03-01&rft.volume=44&rft.issue=3&rft.spage=408&rft.epage=416&rft.pages=408-416&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-016-3508-0&rft_dat=%3Cproquest_cross%3E4312388061%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1865256358&rft_id=info:pmid/27613541&rfr_iscdi=true |